This article has Open Peer Review reports available.
The novel p.Cys65Tyr mutation in NR5A1gene in three 46,XY siblings with normal testosterone levels and their mother with primary ovarian insufficiency
© Fabbri et al.; licensee BioMed Central Ltd. 2014
Received: 27 March 2013
Accepted: 5 January 2014
Published: 10 January 2014
Disorders of sex development (DSD) is the term used for congenital conditions in which development of chromosomal, gonadal, or phenotypic sex is atypical. Nuclear receptor subfamily 5, group A, member 1 gene (NR5A1) encodes steroidogenic factor 1 (SF1), a transcription factor that is involved in gonadal development and regulates adrenal steroidogenesis. Mutations in the NR5A1 gene may lead to different 46,XX or 46,XY DSD phenotypes with or without adrenal failure. We report a Brazilian family with a novel NR5A1 mutation causing ambiguous genitalia in 46,XY affected individuals without Müllerian derivatives and apparently normal Leydig function after birth and at puberty, respectively. Their mother, who is also heterozygous for the mutation, presents evidence of primary ovarian insufficiency.
Three siblings with 46,XY DSD, ambiguous genitalia and normal testosterone production were included in the study. Molecular analyses for AR, SRD5A2 genes did not reveal any mutation. However, NR5A2 sequence analysis indicated that all three siblings were heterozygous for the p.Cys65Tyr mutation which was inherited from their mother. In silico analysis was carried out to elucidate the role of the amino acid change on the protein function. After the mutation was identified, all sibs and the mother had been reevaluated. Basal hormone concentrations were normal except that ACTH levels were slightly elevated. After 1 mcg ACTH stimulation test, only the older sib showed subnormal cortisol response.
The p.Cys65Tyr mutation located within the second zinc finger of DNA binding domain was considered deleterious upon analysis with predictive algorithms. The identification of heterozygous individuals with this novel mutation may bring additional knowledge on structural modifications that may influence NR5A1 DNA-binding ability, and may also contribute to genotype-phenotype correlations in DSD. The slightly elevated ACTH basal levels in all three patients with 46,XY DSD and the subnormal cortisol response after 1 mcg ACTH stimulation in the older sib indicate that a long-term follow-up for adrenal function is important for these patients. Our data reinforce that NR5A1 analysis must also be performed in 46,XY DSD patients with normal testosterone levels without AR mutations.
Steroidogenic factor 1 (SF1), denominated as nuclear receptor subfamily 5 group A member 1 (NR5A1 [OMIM + 184757]), is a protein that regulates several steps of adrenal and gonadal development [1, 2]. It is encoded by the NR5A1 gene, which is an autosomal gene mapped to 30 kb within 9q33. The NR5A1 gene has one non-translated exon (exon 1), six coding exons (exon 2–7) and six introns [3, 4]. The SF1 protein has 461 amino acids divided in two zinc-finger DNA-binding domains (DBD), a ligand-binding domain (LBD), two functional activation domains (AF-1 and AF-2), an accessory region, and a hinge region . SF1 is extremely conserved among species and it presents 95% overall amino acid identity between human and mouse sequences .
NR5A1 is expressed in the developing urogenital ridge, steroidogenic tissues (such as gonads, adrenals, and placenta), hypothalamus and anterior pituitary [7–9]. In general, it activates the expression of AMH in Sertoli cells leading to the regression of Müllerian structures [1, 2, 9]; in Leydig cells, it activates the expression of several enzymes involved in steroidogenesis, resulting in the virilization of external genitalia and testicular descent [1, 2, 9]; and, in ovaries, NR5A1 is expressed in the granulosa and theca cells where it regulates genes required for ovarian steroidogenesis and follicle growth maturation [8, 9]. Genes such as: CYPs, HSD3B2, StAR, SOX9, NR0B1, and others are among the gene targets subject to SF1 transcriptional regulation . As an essential transcription regulator for adrenal and gonadal development, SF1 is very important in sex differentiation processes, although it also plays important physiological roles in the central nervous system . Therefore, mutations in NR5A1 may lead to Disorders of Sex Development (DSD) defined as incomplete or disordered gonadal or genital development, causing divergences between genetic sex, gonadal sex and phenotypic sex [11, 12].
p.Gly35Glu and p.Arg92Gln were the first two mutations described in human NR5A1. They had been identified in patients with primary adrenal insufficiency, complete gonadal dysgenesis and Müllerian duct persistence [13, 14]. Over 50 mutations have been reported mainly in 46,XY DSD individuals with apparently normal adrenal function, but they were also found in 46,XX individuals with primary ovarian insufficiency and normal female phenotype and male individuals with infertility [15–19]. In addition, several reports demonstrated that NR5A1 variations might be associated with hypospadias, anorchia, and with some cases of adrenal tumors and endometriosis [20, 21].
Such findings indicate a complex phenotype expressivity, with different penetrance and variable inheritance pattern for NR5A1 mutations. Therefore, it is difficult to establish a direct phenotype-genotype correlation . Recently, some authors have reported heterozygous loss-of-function NR5A1 mutations in patients with clinical features of androgen insensitivity syndrome (AIS) and apparently normal Leydig and Sertoli cell function but without mutations in the androgen receptor gene (AR) [23–25].
In this report, we describe the novel c.195G > A NR5A1 mutation identified in three siblings with 46,XY DSD. They were born of non-consanguineous parents, and had been brought to medical care due to ambiguous genitalia. All of them had normal testosterone levels in first months of life and the proband had normal male puberty. Molecular analyses showed that the putative p.Cys65Tyr missense was inherited from the mother, who presented with signs of primary ovarian insufficiency.
The study was undertaken under an institutionally approved ethic protocol and informed consent was obtained from all subjects and relatives.
Hormonal values for the three patients
Patient, age (yr)
Micropenis and perineal hypospadia
1.04 (pre hCG) 6.59 (after hCG)
Started spontaneuous puberty
Micropenis and penoscrotal hypospadia
Micropenis, perineal urogenital opening and bilateral cryptorchidism
0.66 (pre hCG) 6.94 (after hCG)
Male: 1.50-12.40 Female (menopause): 25.80-134.80 Children: 0.20-3.80
Male: 1.70-8.60 Female (menopause): 7.70-58.85 Children: 0.20-1.40
Female (menopause): <200.75
8 a.m.: 138.00-690.00 ≥ 551.80*
Tanner I - <0.69
Tanner II - <14.92
Tanner III – 2.25- 27.07
Tanner IV – 6.47-26.37
Tanner V – 6.59-30.54
Male 18–49 yrs: 8.64-29.01
The second sib, currently aged 7 years, was born at term after an uneventful pregnancy. At birth he presented 2-cm phallus, penoscrotal hypospadias and palpable gonads in the labioscrotal folds. His karyotype was 46,XY. Pelvic ultrasound did not show mullerian derivatives. Hormone investigation was performed at 2 month of age and resulted in high LH level with normal levels of FSH and testosterone (Table 1). He was assigned as male and had the hypospadias repaired. In a recent evaluation of the adrenal function, basal levels of ACTH and cortisol were, respectively, slightly elevated and normal (Table 1). Upon 1 mcg ACTH stimulation, cortisol response was normal (Table 1).
The third sib, who is currently 6 years old, was born at term after an uneventful pregnancy with a 1.3-cm phallus, a single perineal urogenital opening, and palpable gonads, both in the inguinal region. He also had a normal 46,XY karyotype. Pelvic ultrasound did not show mullerian derivatives. At the age of 2 months, hormone levels for FSH, LH, testosterone and dihydrotestosterone were normal (Table 1). He was assigned as male and underwent hypospadias repair and orchidopexy. Recent evaluation of the adrenal function revealed slightly elevated basal ACTH and normal basal cortisol levels (Table 1). He also had a normal cortisol response upon 1 mcg ACTH stimulation test (Table 1).
The 33-year-old mother had throughout hormone evaluation after identifying the NR5A1 mutation (see below). Hormonal results revealed high FSH, normal to high LH and normal to low estradiol levels with normal adrenal function (Table 1). She also reported irregular menses and hot flushes, suggesting primary ovarian insufficiency.
Genomic DNAs from patients and parents were purified from peripheral leukocytes by proteinase K lysis, phenol/chloroform extraction, and ethanol precipitation, according to standard techniques. Sequencing of both AR (androgen receptor) and SRD5A2 (5α-reductase) genes had been performed as described elsewhere [26, 27]. The NR5A1 exons and 5’ and 3’ untranslated flanking regions were amplified by polymerase chain reaction (PCR) using specific primers designed based on the normal gene sequence (ENSG00000136931, http://www.ensembl.org). Independent PCR fragments were purified in 1% agarose gel electrophoresis with the Wizard SV Gel and PCR clean-up system (Promega, Madison, WI, USA), and both sense and antisense strands were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Grand Island, NY, USA) with the same primers used in PCR reactions. The Chromas Lite 2.0 (Technelysium Pty Ltd) and CLC Sequence Viewer v.6.8.1 free software (CLC bio) were used to analyze and compare sequences with the reference NR5A1 sequence. Structural analyses were performed using PDB ID: 2FF0 – chain A as template. The native and mutant models were constructed by SWISS MODEL web-served program. Internal contacts were evaluated by STING Millenium (http://www.cbi.cnptia.embrapa.br) and visualized by PyMol®.
DNA sequence analyses of AR and SRD5A2 genes did not show any mutation. However, NR5A1 gene sequencing revealed a novel heterozygous transition G > A within exon 3 in all three siblings as well as in their mother (Figure 1B). The nucleotide change c.195G > A is predicted to cause the substitution of a cysteine by a tyrosine at the amino acid residue 65 (p.Cys65Tyr).
Three predictive methods to evaluate the effect of the amino acid substitution were used: PolyPhen (Polymorphism Phenotyping) that gives scores ranging from 0 (neutral) to a positive (damaging) number; SIFT (Sorting Intolerant From Tolerant) whose scores range from 0 (damaging) to 1 (neutral); and Aling GV-GD that classifies the amino acid change into classes ranging from C0 to C65, where C0 is considered tolerant and C65 deleterious [29, 30]. The p.Cys65Tyr mutation resulted in PolyPhen score of 1.0, SIFT score of 0 and Aling GV-GD put it into class C65 indicating a protein damage, probably leading to patients’ phenotypes. In order to discard the possibility of the nucleotide variation being a frequent polymorphism, 86 healthy controls (172 alleles) were analyzed and c.195G > A was not identified in any allele.
We present here the follow-up of patients with 46,XY DSD in a Brazilian family. The three sibs presented with different hormone profiles in the first year of life. Testosterone levels were normal for all of them; however, sib 1 and sib 2 presented isolated elevation of FSH and LH levels, respectively, whereas sib 3 had normal levels for both FSH and LH. Initially, AR and SRD5A2 gene sequence analyses had been performed due to 46,XY karyotype, ambiguous genitalia without Müllerian derivatives and normal production of testosterone. As mutations in those genes had not been identified, patients remained idiopathic and the etiologic diagnosis was not defined, even though the severity of ambiguous genitalia and the familial recurrence clearly indicated a genetic origin. After long-term follow-up, the etiology of 46,XY DSD had been solved by the identification of p.Cys65Tyr mutation in the NR5A1 gene which was investigated based on the recent description of variable phenotypic expression as a result of different NR5A1 mutations, and also based on the possibility of a mutation inheritance from a fertile mother, which mimicked an X-linked recessive pattern [23–25].
Most 46,XY patients with NR5A1 loss-of-function mutations have had biological markers that evidenced gonadal dysgenesis, i.e.: LH and FSH levels were usually elevated, AMH levels, if measured, were low, and Leydig cell function, indicated by low levels of testosterone, was invariably defective . Testosterone levels in the three patients were normal during the first year of life and puberty development of the proband also indicated normal Leydig cell function after birth. In addition, Müllerian derivatives were not found suggesting that Sertoli cell function was also normal during primary sex differentiation. As discussed by Tantawy et al., there are very few reports on 46,XY DSD cases that had puberty development and normal male testosterone production inducing spontaneous virilization, however long-term follow-up indicated a progressive gonadal failure with elevated FSH in such cases. Although the proband described here developed normal puberty, he persisted with high levels of FSH from first months of life till puberty suggesting some degree of tubular defect that might cause fertility impairment.
Recently, Wu et al.  speculated if SF1 disruption caused by NR5A1 loss-of-function mutations may be associated with functional androgen resistance or altered Leydig cell maturation leading to hyper-responsiveness to postnatal LH stimulation. Our data also suggest such a mechanism and reinforce that, in the absence of AR mutations, NR5A1 gene analysis must be performed in 46,XY DSD despite normal testosterone levels.
Several mutations have been described in NR5A1 in different cases of 46,XY DSD so far [15, 17, 32, 33], however a mutation in the C65 residue has been described here for the first time. The nucleotide change c.195G > A results in p.Cys65Tyr missense which is predicted as damaging by in silico tools. It is well known that cysteine influences the overall three-dimensional structure of proteins. Its sulfur group reacts quite readily with other sulfur groups, forming disulfide bonds that play important role in the folding and stability of proteins. Cysteine residues also play a valuable role in crosslinking proteins, which increases protein rigidity and also confers proteolytic resistance . Conversely, tyrosine is an aromatic and partially hydrophobic amino acid . The aromatic side chain is usually involved in stacking interactions with other aromatic side chains . Tyrosine can also be involved in phosphorylation within intracellular proteins . In the structural analyses, a previously inexistent hydrophobic interaction with C55 was observed for Y65 residue. In addition, this novel mutation is located within the second zinc finger of DNA binding domain where C65 itself binds directly to the zinc atom , therefore the change to tyrosine may influence NR5A1 DNA-binding ability by destabilizing zinc-finger conformation. Although functional analyses will be further necessary for formal demonstration of a deleterious effect for p.Cys65Tyr mutation, both predictive and structural analyses indicate that it might correlate with the DSD phenotype in the three heterozygous siblings. Their fertile 33-year-old mother who is also heterozygous for the mutation reported irregular menses and hot flushes, after molecular diagnosis. Upon endocrine investigation, gonadotropin and estradiol levels suggest primary ovarian insufficiency. Taken together, those data indicate that p.Cys65Tyr mutation may also compromise the ovarian functional maintenance similar to other NR5A1 mutations described in the literature [15–17].
Considering the slightly elevated basal ACTH levels in all three patients with 46,XY DSD and the subnormal cortisol response after stimulation test with 1 mcg ACTH in the proband, it may be inferred that p.Cys65Tyr mutation could have a late-onset effect upon adrenal function, justifying a long term follow-up on such patients.
In conclusion, based on recent knowledge concerning the phenotypic expression of NR5A1 mutations, the analysis of this gene becomes an important tool not only for diagnosing patients with DSD including the cases with normal testosterone secretion without AR mutations, but also for identifying their female relatives at risk of developing primary ovarian insufficiency and allowing reproductive counseling as well as potentially assisted reproductive techniques.
Written informed consent was obtained from each member of the family for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal.
Helena Campos Fabbri, Juliana Gabriel Ribeiro de Andrade shared first authorship.
Authors would like to thank Mr. Wanderley Pedroso da Graça from Laboratório Nacional de Biociências, CNPEM/ABTLuS sequencing facility and also Mrs. Alessandra Oliveira from Laboratório Multiusuário, CBMEG, UNICAMP. The authors address a special thanks to Mrs. Cristiane dos Santos Cruz Piveta for technical support. This work was supported by grants # 2009/08320-9 and scholarships # 2008/03168-1 (FCS), # 2008/01964-5 (RJP) and # 2011/02865-3 (HCF) from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). This work was also supported by grants from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) to FLC and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - Brasil) to ATMG, GGJ and MPM.
- Luo X, Ikeda Y, Parker KL: A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell. 1994, 77: 481-490. 10.1016/0092-8674(94)90211-9.View ArticlePubMedGoogle Scholar
- Lin L, Achermann JC: Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development. Sex Dev. 2008, 2: 200-209. 10.1159/000152036.View ArticlePubMedPubMed CentralGoogle Scholar
- Wong M, Ramayya MS, Chrousos GP, Driggers PH, Parker KL: Cloning and sequence analysis of the human gene encoding steroidogenic factor 1. J Mol Endocrinol. 1996, 17: 139-147. 10.1677/jme.0.0170139.View ArticlePubMedGoogle Scholar
- Kimura R, Yoshii H, Nomura M, Kotomura N, Mukai T, Ishihara S, Ohba K, Yanase T, Gotoh O, Nawata H, Morohashi K: Identification of novel first exons in Ad4BP/SF-1 (NR5A1) gene and their tissue- and species-specific usage. Biochem Biophys Res Commun. 2000, 278 (Suppl 1): 63-71.View ArticlePubMedGoogle Scholar
- Hoivik EA, Lewis AE, Aumo L, Bakke M: Molecular aspects of steroidogenic factor 1 (SF-1). Mol Cell Endocrinol. 2010, 315 (Suppl 1–2): 27-39.View ArticlePubMedGoogle Scholar
- Ohno CK, Petkovich M: FTZ-F1 beta, a novel member of the Drosophila nuclear receptor family. Mech Dev. 1993, 40: 13-24. 10.1016/0925-4773(93)90084-B.View ArticlePubMedGoogle Scholar
- Parker KL, Rice DA, Lala DS, Ikeda Y, Luo X, Wong M, Bakke M, Zhao L, Frigeri C, Hanley NA, Stallings N, Schimmer BP: Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog Horm Res. 2002, 57: 19-36. 10.1210/rp.57.1.19.View ArticlePubMedGoogle Scholar
- Zhao H, Li Z, Cooney AJ, Lan ZJ: Orphan nuclear receptor function in the ovary. Front Biosci. 2007, 12: 3398-3405. 10.2741/2321.View ArticlePubMedGoogle Scholar
- Buaas FW, Gardiner JR, Clayton S, Val P, Swain A: In vivo evidence for the crucial role of SF1 in steroid-producing cells of the testis, ovary and adrenal gland. Development. 2012, 139: 4561-4570. 10.1242/dev.087247.View ArticlePubMedPubMed CentralGoogle Scholar
- Büdefeld T, Tobet SA, Majdic G: Steroidogenic factor 1 and the central nervous system. J Neuroendocrinol. 2012, 24: 225-235. 10.1111/j.1365-2826.2011.02174.x.View ArticlePubMedGoogle Scholar
- Hughes IA, Houk C, Ahmed SF, Lee PA, Group LC, Group EC: Consensus statement on management of intersex disorders. Arch Dis Child. 2006, 91: 554-563.View ArticlePubMedPubMed CentralGoogle Scholar
- Nabhan ZM, Lee PA: Disorders of sex development. Curr Opin Obstet Gynecol. 2007, 19: 440-445. 10.1097/GCO.0b013e3282eeb13d.View ArticlePubMedGoogle Scholar
- Achermann JC, Ito M, Hindmarsh PC, Jameson JL: A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet. 1999, 22 (Suppl 2): 125-126.PubMedGoogle Scholar
- Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, Jameson JL: Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. J Clin Endocrinol Metab. 2002, 87 (Suppl 4): 1829-1833.View ArticlePubMedGoogle Scholar
- Lourenco D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, Boudjenah R, Guerra-Junior G, Maciel-Guerra AT, Achermann JC, McElreavey K, Bashamboo A: Mutations in the NR5A1 associated with ovarian insufficiency. New Eng J Med. 2009, 360: 1200-1210. 10.1056/NEJMoa0806228.View ArticlePubMedPubMed CentralGoogle Scholar
- Philibert P, Paris F, Lakhal B, Audran F, Gaspari L, Saâd A, Christin-Maître S, Bouchard P, Sultan C: NR5A1 (SF-1) gene variants in a group of 26 young women with XX primary ovarian insufficiency. Fertil Steril. 2013, 99 (Suppl 2): 484-489.View ArticlePubMedGoogle Scholar
- Camats N, Pandey AV, Fernandez-Cancio M, Andaluz P, Janner M, Toran N, Moreno F, Bereket A, Akcay T, García-García E, Muñoz MT, Gracia R, Nistal M, Castaño L, Mullis PE, Carrascosa A, Audí L, Flück CE: Ten novel mutations in the NR5A1 gene cause Disordered Sex Development in 46, XY and Ovarian Insufficiency in 46,XX individuals. Clin Endocrinol Metab. 2012, 97 (Suppl 7): 1294-1306.View ArticleGoogle Scholar
- Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Sebire NJ, Montjean D, Bignon-Topalovic J, Mandelbaum J, Siffroi JP, Christin-Maitre S, Radhakrishna U, Rouba H, Ravel C, Seeler J, Achermann JC, McElreavey K: Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. Am J Hum Genet. 2010, 87: 505-512. 10.1016/j.ajhg.2010.09.009.View ArticlePubMedPubMed CentralGoogle Scholar
- Röpke A, Tewes AC, Gromoll J, Kliesch S, Wieacker P, Tüttelmann F: Comprehensive sequence analysis of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile males. Eur J Hum Genet. 2013, in pressGoogle Scholar
- Brauner R, Neve M, Allali S, Trivin C, Lottmann H, Bashamboo A, McElreavey K: Clinical, biological and genetic analysis of anorchia in 26 boys. PLoS One. 2011, 6: e23292-10.1371/journal.pone.0023292.View ArticlePubMedPubMed CentralGoogle Scholar
- Ferraz-de-Souza B, Lin L, Achermann JC: Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol Cell Endocrinol. 2011, 336 (Suppl 1–2): 198-205.View ArticlePubMedPubMed CentralGoogle Scholar
- De Mello MP, França ESS, Fabbri HC, Maciel-Guerra AT, Guerra-Júnior G: Multifunctional role of steroidogenic factor 1 and disorders of sex development. Arq Bras Endocrinol Metabol. 2011, 55 (Suppl 8): 607-612.View ArticleGoogle Scholar
- Coutant R, Mallet D, Lahlou N, Bouhours-Nouet N, Guichet A, Coupris L, Croué A, Morel Y: Heterozygous mutation of steroidogenic factor-1 in 46,XY subjects may mimic partial androgen insensitivity syndrome. J Clin Endocrinol Metab. 2007, 92: 2866-2873. 10.1210/jc.2007-0336.View ArticleGoogle Scholar
- van Silfhout A, Boot AM, Dijkhuizen T, Hoek A, Nijman R, Sikkema-Raddatz B, van Ravenswaaij-Arts CM: A unique 970 kb microdeletion in 9q33.3 including the NR5A1 gene in a 46,XY female. Eur J Med Genet. 2009, 52: 157-160. 10.1016/j.ejmg.2009.02.009.View ArticlePubMedGoogle Scholar
- Wu JY, McGown IN, Lin L, Achermann JC, Harris M, Coley DM, Aftimos S, Neville KA, Choong CS, Cotterill AM: A novel NR5A1 variant in an infant with elevated testosterone from an Australian cohort of 46,XY patients with disorders of sex development. Clin Endocrinol. 2013, 78: 545-550. 10.1111/cen.12012.View ArticleGoogle Scholar
- Veiga-Junior NN, Medaets PA, Petroli RJ, Calais FL, de Mello MP, Castro CC, Guaragna-Filho G, Sewaybricker LE, Marques-de-Faria AP, Maciel-Guerra AT, Guerra-Junior G: Clinical and laboratorial features that may differentiate 46, XY DSD due to partial androgen insensitivity and 5α-reductase type 2 deficiency. Int J Endocrinol. 2012, 2012: 964876-View ArticlePubMedGoogle Scholar
- Petroli RJ, Maciel-Guerra AT, Soardi FC, de Calais FL, Guerra-Junior G, de Mello MP: Severe forms of partial androgen insensitivity syndrome due to p.L830F novel mutation in androgen receptor gene in a Brazilian family. BMC Res Notes. 2011, 4: 173-10.1186/1756-0500-4-173.View ArticlePubMedPubMed CentralGoogle Scholar
- Little TH, Zhang Y, Matulis CK, Weck J, Zhang Z, Ramachandran A, Mayo KE, Radhakrishnan I: Sequence-specific deoxyribonucleic acid (DNA) recognition by steroidogenic factor 1: a helix at the carboxy terminus of the DNA binding domain is necessary for complex stability. Mol Endocrinol. 2006, 20 (Suppl 4): 831-843.View ArticlePubMedGoogle Scholar
- Ng PC, Henikoff S: Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet. 2006, 7: 61-80. 10.1146/annurev.genom.7.080505.115630.View ArticlePubMedGoogle Scholar
- Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV: Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res. 2006, 34 (Suppl 5): 1317-1325.View ArticlePubMedPubMed CentralGoogle Scholar
- Tantawy S, Lin L, Akkurt I, Borck G, Klingmüller D, Hauffa BP, Krude H, Biebermann H, Achermann JC, Köhler B: Testosterone production during puberty in two 46, XY patients with disorders of sex development and novel NR5A1 (SF-1) mutations. Eur J Endocrinol. 2012, 167: 125-130. 10.1530/EJE-11-0944.View ArticlePubMedPubMed CentralGoogle Scholar
- Philibert P, Leprieur E, Zenaty D, Thibaud E, Polak M, Frances AM, Lespinasse J, Raingeard I, Servant N, Audran F, Paris F, Sultan C: Steroidogenic factor-1 (SF-1) gene mutation as a frequent cause of primary amenorrhea in 46, XY female adolescents with low testosterone concentration. Reprod Biol Endocrinol. 2010, 8: 28-10.1186/1477-7827-8-28.View ArticlePubMedPubMed CentralGoogle Scholar
- Barbaro M, Cools M, Looijenga LHJ, Drop SLS, Wedell A: Partial deletion of the NR5A1 (SF1) gene detected by synthetic probe MLPA in a patient with XY Gonadal disorder of sex development. Sex Dev. 2011, 5: 181-187. 10.1159/000328821.View ArticlePubMedGoogle Scholar
- Betts MJ, Russell RB: Amino acid properties and consequences of substitutions. Bioinformatics for Geneticists. Edited by: Barnes MR, Gray IC. 2003, West Sussex: John Wiley & Sons, Ltd, 289-313.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2350/15/7/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.